These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19763356)

  • 21. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
    Mannucci PM; Kempton C; Millar C; Romond E; Shapiro A; Birschmann I; Ragni MV; Gill JC; Yee TT; Klamroth R; Wong WY; Chapman M; Engl W; Turecek PL; Suiter TM; Ewenstein BM;
    Blood; 2013 Aug; 122(5):648-57. PubMed ID: 23777763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
    De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo and in vitro processing of recombinant pro-von Willebrand factor.
    Turecek PL; Váradi K; Schlokat U; Pichler L; Dorner F; Schwarz HP
    Histochem Cell Biol; 2002 Feb; 117(2):123-9. PubMed ID: 11935288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic.
    Kawasaki T; Kaida T; Arnout J; Vermylen J; Hoylaerts MF
    Thromb Haemost; 1999 Feb; 81(2):306-11. PubMed ID: 10064011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations.
    Rastegar-Lari G; Ajzenberg N; Ribba AS; Vereycken-Holler V; Legendre P; Villoutreix B; Meyer D; Baruch D
    Thromb Haemost; 2001 Dec; 86(6):1459-65. PubMed ID: 11776314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease.
    Hommais A; Stépanian A; Fressinaud E; Mazurier C; Pouymayou K; Meyer D; Girma JP; Ribba AS
    Thromb Haemost; 2006 May; 95(5):776-81. PubMed ID: 16676067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by furin-mediated propeptide removal in vitro.
    Schlokat U; Fischer BE; Herlitschka S; Antoine G; Preininger A; Mohr G; Himmelspach M; Kistner O; Falkner FG; Dorner F
    Biotechnol Appl Biochem; 1996 Dec; 24(3):257-67. PubMed ID: 8969456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New assay for measuring binding of platelet glycoprotein IIb/IIIa to unpurified von Willebrand factor.
    Veyradier A; Jumilly AL; Ribba AS; Obert B; Houllier A; Meyer D; Girma JP
    Thromb Haemost; 1999 Jul; 82(1):134-9. PubMed ID: 10456467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S; Carlson M; Hillarp A
    Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
    Ramasamy I; Farrugia A; Tran E; Anastasius V; Charnock A
    Biologicals; 1998 Jun; 26(2):155-66. PubMed ID: 9811523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
    Neugebauer BM; Goy C; Budek I; Seitz R
    Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of VWF in the immunogenicity of FVIII.
    Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S
    Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease.
    Gritsch H; Schrenk G; Weinhappl N; Mellgård B; Ewenstein B; Turecek PL
    J Blood Med; 2022; 13():649-662. PubMed ID: 36405429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of nano-electrospray gas-phase electrophoretic mobility macromolecular analysis and matrix-assisted laser desorption/ionization linear time-of-flight mass spectrometry for the characterization of the recombinant coagulation glycoprotein von Willebrand factor.
    Kemptner J; Marchetti-Deschmann M; Müller R; Ivens A; Turecek P; Schwarz HP; Allmaier G
    Rapid Commun Mass Spectrom; 2010 Mar; 24(6):761-7. PubMed ID: 20169558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endoplasmic reticulum retention and prolonged association of a von Willebrand's disease-causing von Willebrand factor variant with ERp57 and calnexin.
    Allen S; Goodeve AC; Peake IR; Daly ME
    Biochem Biophys Res Commun; 2001 Jan; 280(2):448-53. PubMed ID: 11162537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.